Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)

  Genzyme Receives Company Award from European Organisation for Rare Diseases
  (EURORDIS)

Business Wire

CAMBRIDGE, Mass. -- February 27, 2013

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that
it has received a Company Award from EURORDIS, the largest European patient
organization in the field of rare diseases. The EURORDIS Company Award
recognizes the outstanding accomplishments of companies dedicated to rare
diseases. Genzyme was honored for pioneering the development and delivery of
therapies for rare diseases, its longstanding support of patient
organizations, including EURORDIS, as well as initiatives to increase patient
access to Genzyme treatments.

EURORDIS Award recipients are selected by the EURORDIS Board of Directors,
from over 100 nominations received from EURORDIS members (rare disease patient
advocacy groups from all Europe), volunteers and staff, with the aim of
promoting leadership and excellence for people living with rare diseases.
Genzyme’s Senior Vice President of Rare Diseases in Europe, Hilde Furberg,
accepted the award yesterday during the EURORDIS Black Pearl Gala Dinner in
Brussels as EURORDIS began its activities to recognize International Rare
Disease Day.

“Genzyme has been partnering with patient advocacy organizations globally from
our earliest days to be sure the community’s needs and perspectives are always
represented within our organization, and the contributions of these
organizations remain central to Genzyme and our ability to bring therapies to
patients,” said Genzyme’s Head of Rare Diseases, Rogerio Vivaldi, MD. “As we
approach Rare Disease Day, a day made possible because of EURORDIS, Genzyme
wants to thank all of the patient organizations and communities who work daily
to improve the lives of patients living with rare diseases. Their pioneering
spirit will continue to inspire Genzyme.”

Yann Le Cam, Chief Executive Officer of EURORDIS, said, "We are honored to
acknowledge the commitment and achievements of this year’s recipients of the
EURORDIS Awards on the occasion of Rare Disease Day 2013. Each of this year’s
ten awardees contributes in their own unique way toward fostering the goals of
cooperation embodied in this year’s Rare Disease Day slogan: ‘Rare Disorders
without Borders.’ We are proud that the rare disease community is becoming a
model for multi-stakeholder partnership and international collaboration as
well as for solidarity and unity throughout Europe.”

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. That goal guides and inspires us every day.
Genzyme’s portfolio of transformative therapies, which are marketed in
countries around the world, represents groundbreaking and life-saving advances
in medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies, with a
shared commitment to improving the lives of patients. Learn more at
www.genzyme.com.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Genzyme^® is a registered trademark. All rights reserved

Contact:

Genzyme
Lori Gorski, 617-768-9344
Lori.gorski@genzyme.com